FI79411B - Foerfarande foer vaerdering av cellernas malignitet, vid foerfarandet anvaendbara antikroppar, antigener, deras framstaellning och anvaendning. - Google Patents

Foerfarande foer vaerdering av cellernas malignitet, vid foerfarandet anvaendbara antikroppar, antigener, deras framstaellning och anvaendning. Download PDF

Info

Publication number: FI79411B
Authority: FI; Finland
Prior art keywords: pro; gly; ala; ser; thr
Prior art date: 1982-11-04

Application number

FI833952A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI833952A (fi

FI833952A0 (fi

Inventor

Martin J Cline

Dennis J Slamon

Original Assignee

Univ California

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-11-04

Filing date

1983-10-28

Publication date

1989-08-31

1983-10-28 Application filed by Univ California filed Critical Univ California

1983-10-28 Publication of FI833952A0 publication Critical patent/FI833952A0/fi

1984-05-05 Publication of FI833952A publication Critical patent/FI833952A/fi

1989-08-31 Application granted granted Critical

1989-08-31 Publication of FI79411B publication Critical patent/FI79411B/fi

Links

210000004027 cell Anatomy 0.000 claims description 81
206010028980 Neoplasm Diseases 0.000 claims description 56
238000000034 method Methods 0.000 claims description 53
108700020796 Oncogene Proteins 0.000 claims description 42
230000014509 gene expression Effects 0.000 claims description 41
108020004999 messenger RNA Proteins 0.000 claims description 36
230000003211 malignant effect Effects 0.000 claims description 28
201000011510 cancer Diseases 0.000 claims description 26
230000036210 malignancy Effects 0.000 claims description 26
108010038807 Oligopeptides Proteins 0.000 claims description 25
102000015636 Oligopeptides Human genes 0.000 claims description 25
108090000623 proteins and genes Proteins 0.000 claims description 25
102000043276 Oncogene Human genes 0.000 claims description 18
108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
230000000890 antigenic effect Effects 0.000 claims description 15
150000001413 amino acids Chemical group 0.000 claims description 13
102000004169 proteins and genes Human genes 0.000 claims description 13
239000012530 fluid Substances 0.000 claims description 10
230000001413 cellular effect Effects 0.000 claims description 9
125000003729 nucleotide group Chemical group 0.000 claims description 8
239000002773 nucleotide Substances 0.000 claims description 7
102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 6
101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 6
101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 6
102000040430 polynucleotide Human genes 0.000 claims description 6
108091033319 polynucleotide Proteins 0.000 claims description 6
239000002157 polynucleotide Substances 0.000 claims description 6
230000008569 process Effects 0.000 claims description 6
230000001131 transforming effect Effects 0.000 claims description 6
102000053602 DNA Human genes 0.000 claims description 5
108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 claims description 5
102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 claims description 5
238000003745 diagnosis Methods 0.000 claims description 5
229920005989 resin Polymers 0.000 claims description 5
239000011347 resin Substances 0.000 claims description 5
230000001177 retroviral effect Effects 0.000 claims description 5
MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 claims description 4
SITWEMZOJNKJCH-UHFFFAOYSA-N L-alanine-L-arginine Natural products CC(N)C(=O)NC(C(O)=O)CCCNC(N)=N SITWEMZOJNKJCH-UHFFFAOYSA-N 0.000 claims description 4
SNGZLPOXVRTNMB-LPEHRKFASA-N Pro-Ser-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CO)C(=O)N2CCC[C@@H]2C(=O)O SNGZLPOXVRTNMB-LPEHRKFASA-N 0.000 claims description 4
125000000539 amino acid group Chemical group 0.000 claims description 4
108010057821 leucylproline Proteins 0.000 claims description 4
239000003550 marker Substances 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
108010077112 prolyl-proline Proteins 0.000 claims description 4
108020004414 DNA Proteins 0.000 claims description 3
RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 claims description 3
108060006706 SRC Proteins 0.000 claims description 3
102000001332 SRC Human genes 0.000 claims description 3
230000015572 biosynthetic process Effects 0.000 claims description 3
230000000295 complement effect Effects 0.000 claims description 3
230000000694 effects Effects 0.000 claims description 3
230000001939 inductive effect Effects 0.000 claims description 3
229920005990 polystyrene resin Polymers 0.000 claims description 3
101710147844 Myb protein Proteins 0.000 claims description 2
108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 claims description 2
102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 claims description 2
239000013599 cloning vector Substances 0.000 claims description 2
208000032839 leukemia Diseases 0.000 claims 3
108020004511 Recombinant DNA Proteins 0.000 claims 2
210000000601 blood cell Anatomy 0.000 claims 2
108091034117 Oligonucleotide Proteins 0.000 claims 1
SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 claims 1
229940127089 cytotoxic agent Drugs 0.000 claims 1
239000002254 cytotoxic agent Substances 0.000 claims 1
231100000599 cytotoxic agent Toxicity 0.000 claims 1
MGHPNCMVUAKAIE-UHFFFAOYSA-N diphenylmethanamine Chemical compound C=1C=CC=CC=1C(N)C1=CC=CC=C1 MGHPNCMVUAKAIE-UHFFFAOYSA-N 0.000 claims 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
238000010348 incorporation Methods 0.000 claims 1
108010053725 prolylvaline Proteins 0.000 claims 1
108090000765 processed proteins & peptides Proteins 0.000 description 28
210000001519 tissue Anatomy 0.000 description 27
108091032973 (ribonucleotides)n+m Proteins 0.000 description 23
239000000047 product Substances 0.000 description 19
239000000427 antigen Substances 0.000 description 17
108091007433 antigens Proteins 0.000 description 17
102000036639 antigens Human genes 0.000 description 17
238000009396 hybridization Methods 0.000 description 14
102000004196 processed proteins & peptides Human genes 0.000 description 11
241000287828 Gallus gallus Species 0.000 description 9
241000251539 Vertebrata <Metazoa> Species 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
235000013330 chicken meat Nutrition 0.000 description 9
238000002474 experimental method Methods 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 7
210000001161 mammalian embryo Anatomy 0.000 description 7
210000002257 embryonic structure Anatomy 0.000 description 6
230000008175 fetal development Effects 0.000 description 6
239000000203 mixture Substances 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
241001430294 unidentified retrovirus Species 0.000 description 6
108020004705 Codon Proteins 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
239000012634 fragment Substances 0.000 description 5
239000012528 membrane Substances 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
241000699670 Mus sp. Species 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
210000003754 fetus Anatomy 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
239000000523 sample Substances 0.000 description 4
239000013598 vector Substances 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
241000282412 Homo Species 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
101150001535 SRC gene Proteins 0.000 description 3
ADJDNJCSPNFFPI-FXQIFTODSA-N Ser-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO ADJDNJCSPNFFPI-FXQIFTODSA-N 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000004720 fertilization Effects 0.000 description 3
239000007850 fluorescent dye Substances 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
210000002826 placenta Anatomy 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
241000894007 species Species 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
108700026239 src Genes Proteins 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000212384 Bifora Species 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
108091000080 Phosphotransferase Proteins 0.000 description 2
BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
238000000246 agarose gel electrophoresis Methods 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
230000013020 embryo development Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000002502 liposome Substances 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
208000025113 myeloid leukemia Diseases 0.000 description 2
102000020233 phosphotransferase Human genes 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
XWZAWHJNTHSHGD-SIDOVBMKSA-N (2S)-6-amino-N-[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]propanoyl]amino]hexanamide Polymers CC(C)C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccccc1)C(N)=O XWZAWHJNTHSHGD-SIDOVBMKSA-N 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000713838 Avian myeloblastosis virus Species 0.000 description 1
108090001008 Avidin Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
208000005443 Circulating Neoplastic Cells Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
241000252203 Clupea harengus Species 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
241001290006 Fissurella Species 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
108010058398 Macrophage Colony-Stimulating Factor Receptor Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108010020361 Oncogene Protein gp140(v-fms) Proteins 0.000 description 1
108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 1
108010054076 Oncogene Proteins v-myb Proteins 0.000 description 1
241000237988 Patellidae Species 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 1
102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 1
108010021833 Proto-Oncogene Proteins c-yes Proteins 0.000 description 1
102000007696 Proto-Oncogene Proteins c-yes Human genes 0.000 description 1
108091008109 Pseudogenes Proteins 0.000 description 1
108091034057 RNA (poly(A)) Proteins 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
101900269587 Rous sarcoma virus Tyrosine-protein kinase transforming protein Src Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
108700005077 Viral Genes Proteins 0.000 description 1
101710101493 Viral myc transforming protein Proteins 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
108010087924 alanylproline Proteins 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
238000003556 assay Methods 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000011616 biotin Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
-1 c-mos Proteins 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000035558 fertility Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
235000013569 fruit product Nutrition 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108010074605 gamma-Globulins Proteins 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
235000019514 herring Nutrition 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
201000005202 lung cancer Diseases 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
230000013011 mating Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
108700021654 myb Genes Proteins 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
210000004681 ovum Anatomy 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000010257 thawing Methods 0.000 description 1
108010061238 threonyl-glycine Proteins 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/82—Translation products from oncogenes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Hematology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Urology & Nephrology (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oncology (AREA)
Physics & Mathematics (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Biophysics (AREA)
Zoology (AREA)
Cell Biology (AREA)
Wood Science & Technology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Bioinformatics & Cheminformatics (AREA)
Hospice & Palliative Care (AREA)
General Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Plant Pathology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

FI833952A 1982-11-04 1983-10-28 Foerfarande foer vaerdering av cellernas malignitet, vid foerfarandet anvaendbara antikroppar, antigener, deras framstaellning och anvaendning. FI79411B (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US43925282A	1982-11-04	1982-11-04
US43925282		1982-11-04
US49602783A	1983-05-19	1983-05-19
US49602783		1983-05-19

Publications (3)

Publication Number	Publication Date
FI833952A0 FI833952A0 (fi)	1983-10-28
FI833952A FI833952A (fi)	1984-05-05
FI79411B true FI79411B (fi)	1989-08-31

Family

ID=27031979

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI833952A FI79411B (fi)	1982-11-04	1983-10-28	Foerfarande foer vaerdering av cellernas malignitet, vid foerfarandet anvaendbara antikroppar, antigener, deras framstaellning och anvaendning.

Country Status (16)

Country	Link
EP (1)	EP0108564B1 (no)
JP (3)	JPH0728759B2 (no)
AU (1)	AU559912B2 (no)
BR (1)	BR8306175A (no)
CA (1)	CA1252046A (no)
DE (1)	DE3376507D1 (no)
DK (1)	DK498083A (no)
ES (2)	ES8704005A1 (no)
FI (1)	FI79411B (no)
GR (1)	GR78948B (no)
IE (1)	IE56509B1 (no)
IL (1)	IL70067A (no)
NO (1)	NO163986C (no)
NZ (1)	NZ206096A (no)
PH (1)	PH20994A (no)
PT (1)	PT77605B (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6713619B1 (en)	1980-08-29	2004-03-30	Massachusetts Institute Of Technology	Oncogenes and methods for their detection
US4935341A (en) *	1986-06-04	1990-06-19	Whitehead Institute For Biomedical Research	Detection of point mutations in neu genes
ZA84617B (en) *	1983-02-14	1984-09-26	Arup Sen	Synthetic polypeptides from viryl oncogenes
CA1219232A (en) *	1983-08-17	1987-03-17	Richard A. Lerner	Polypeptide-induced monoclonal receptors to protein ligands
US5733738A (en) *	1983-08-17	1998-03-31	Ligand Pharmaceuticals	Polypeptide-induced monoclonal receptors to protein ligands
EP0177814A3 (en) *	1984-09-19	1987-12-02	Cetus Corporation	Peptide antibodies and their use in detecting oncogene products
US4798787A (en) *	1984-09-19	1989-01-17	Cetus Corporation	Peptide antibodies and their use in detecting oncogene products
US4762706A (en) *	1984-10-17	1988-08-09	Cetus Corporation	Peptide antibodies and their use in detecting oncogene products
IL76997A0 (en) *	1984-11-14	1986-04-29	Oncogene Science Inc	Probes and methods useful for detecting chromosomal translocation
US5028527A (en) *	1988-02-22	1991-07-02	Applied Bio Technology	Monoclonal antibodies against activated ras proteins with amino acid mutations at position 13 of the protein
US5081230A (en) *	1987-07-08	1992-01-14	E. I. Dupont Denemours And Company	Monoclonal antibodies reactive with normal and oncogenic forms of the ras p21 protein
US5443956A (en) *	1985-01-29	1995-08-22	Oncogene Science, Inc.	Detection, quantitation and classification of RAS proteins in body fluids and tissues
US6200764B1 (en)	1985-01-29	2001-03-13	Bayer Corporation	Detection, quantitation and classification of ras proteins in body fluids and tissues
CA1296660C (en) *	1985-01-29	1992-03-03	Walter P. Carney	Monoclonal antibody against a ras oncogene p21 related dodecapeptide
US5084380A (en) *	1985-01-29	1992-01-28	Applied Biotechnology	Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
US4898932A (en) *	1985-01-29	1990-02-06	E. I. Du Pont De Nemours And Company	Monoclonal antibodies reactive with activated and oncogenic ras p21 proteins
DE3686304T2 (de) *	1985-04-04	1993-02-11	Univ Georgetown	Typenspezifische papillomavirus-dns-sequenzen und peptide.
EP0203587A3 (en) *	1985-05-30	1989-08-09	F. Hoffmann-La Roche Ag	Ras oncogene peptides and antibodies
EP0206065A3 (en) *	1985-06-27	1989-04-19	James R. Feramisco	Method of detecting oncogene and proto-oncogene related proteins in extracellular biological fluids
US6083709A (en) *	1985-08-21	2000-07-04	Osi Pharmaceuticals, Inc.	Immunoassay for detection of mutant P53 polypeptide in serum
IL79755A0 (en) *	1985-08-21	1986-11-30	Oncogene Science Inc	Immunoassay for detection of ras encoded protein
FR2594833B1 (fr) *	1986-02-26	1989-04-28	Centre Nat Rech Scient	Proteines homologues de celles codees par des oncogenes humains, procede d'obtention de ces proteines et leurs applications immunologiques, physiopathologiques et therapeutiques
FI76119C (fi) *	1986-02-27	1988-09-09	Orion Yhtymae Oy	Kvantitativ bestaemning av nukleinsyramolekyler och reagensfoerpackning som anvaends vid foerfarandet.
EP0246709A1 (en) *	1986-05-20	1987-11-25	Stichting Katholieke Universiteit	Recombinant DNA and cDNA, mRNA, protein, antibodies, and a method of detecting tumor cells
US5320941A (en) *	1986-06-06	1994-06-14	Dallan Young	DNA sequence encoding mas onhcogene, polypeptides encoded therefrom and diagnostic and other methods based therefrom
JPS6374492A (ja) *	1986-09-18	1988-04-04	Hiroshi Shiyuku	モノクロ−ナル抗体
NO881560L (no) *	1987-05-05	1988-11-07	Hope City	Fremgangsmaate for detektering av begynnende resistens motterapeutiske midler i kreftpasienter.
US5085983A (en) *	1988-08-19	1992-02-04	City Of Hope	Detection of human tumor progression and drug resistance
EP0304845A3 (en) *	1987-08-28	1991-03-06	Profile Diagnostic Sciences Inc.	Method and kit for assaying gene expressions
CA1341191C (en) *	1988-04-18	2001-02-27	Robert Allan Weinberg	Detection of neu gene expression and products
AU3533089A (en) *	1988-04-22	1989-11-24	E.I. Du Pont De Nemours And Company	Monoclonal antibodies specific for the harvey, kirsten, and n ras proteins and their use as diagnostic reagents
US5763573A (en) *	1988-08-10	1998-06-09	Chiron Corporation	GTPase activating protein fragments
US5760203A (en) *	1988-08-10	1998-06-02	Chiron Corporation	Gap gene sequences
JPH04500122A (ja) *	1988-08-12	1992-01-09	プロジェンクス・インコーポレイテッド	蛋白リガンドに対するポリペプチド誘発モノクローナル受容体
FR2637600B1 (fr) *	1988-10-11	1992-03-06	Pasteur Institut	Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques
GB9103974D0 (en) *	1991-02-26	1991-04-10	Norsk Hydro As	Therapeutically useful peptides or peptide fragments
NZ592340A (en)	2001-03-27	2012-12-21	Elenore S Bogoch	A method for making a virus vaccine compising Replikin peptides
US7774144B2 (en)	2001-10-26	2010-08-10	Samuel Bogoch	System and method for identifying complex patterns of amino acids
US7189800B2 (en)	2001-03-27	2007-03-13	Samuel Bogoch	Replikin peptides in rapid replication of glioma cells and in influenza epidemics
US7452963B2 (en)	2001-03-27	2008-11-18	Samuel Bogoch	Replikin peptides and antibodies therefore
US7420028B2 (en)	2001-03-27	2008-09-02	Samuel Bogoch	Replikins and methods of identifying replikin-containing sequences
US7894999B2 (en)	2001-03-27	2011-02-22	Samuel Bogoch	Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds
US7442761B2 (en) *	2003-06-06	2008-10-28	Samuel Bogoch	Replikin peptides and uses thereof
EP2261368A1 (en)	2002-03-13	2010-12-15	Genomic Health, Inc.	Gene expression profiling in biopsied tumor tissues
JP4606879B2 (ja)	2002-11-15	2011-01-05	ジェノミックヘルス，インコーポレイテッド	Ｅｇｆｒ陽性癌の遺伝子発現プロファイリング
US20040231909A1 (en)	2003-01-15	2004-11-25	Tai-Yang Luh	Motorized vehicle having forward and backward differential structure
EP1597391B1 (en)	2003-02-20	2008-10-29	Genomic Health, Inc.	Use of intronic rna to measure gene expression
US8494781B2 (en)	2003-06-06	2013-07-23	Samuel Bogoch	Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
DK1641810T4 (en)	2003-06-24	2017-07-03	Genomic Health Inc	Predicting the likelihood of cancer recurrence
ES2905579T3 (es)	2003-07-10	2022-04-11	Genomic Health Inc	Algoritmo del perfil de expresión y prueba para el pronóstico de la recaída del cáncer de mama
EP1699936B1 (en)	2003-12-23	2011-02-09	Genomic Health, Inc.	Universal amplification of fragmented rna
ITPD20040065A1 (it) *	2004-03-15	2004-06-15	Univ Padova	Peptidi della vitronectina e loro impiego terapeutico nella adesione degli osteoblasti
ES2636470T3 (es)	2004-04-09	2017-10-05	Genomic Health, Inc.	Marcadores de expresión génica para predecir la respuesta a la quimioterapia
US9254315B2 (en)	2004-04-28	2016-02-09	Samuel Bogoch	Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds
ATE550440T1 (de)	2004-11-05	2012-04-15	Genomic Health Inc	Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung
JP5020088B2 (ja)	2004-11-05	2012-09-05	ジェノミックヘルス，インコーポレイテッド	遺伝子発現マーカーを使用する、化学療法に対する反応の予測
WO2008140557A2 (en)	2006-10-24	2008-11-20	Samuel Bogoch	A method of predicting influenza outbreaks
WO2008156914A2 (en)	2007-05-30	2008-12-24	Samuel Bogoch	Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture
US9233148B2 (en)	2009-01-09	2016-01-12	Samuel Bogoch	Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
US9328142B2 (en)	2011-05-25	2016-05-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Lipopeptide inhibitors of RAS oncoproteins
CA2842345A1 (en)	2011-07-20	2013-01-24	Samuel Bogoch	Peptides shared among lethal cancers and therapeutic compositions comprising said peptides
CA3036352C (en)	2016-09-09	2020-09-15	De Nora Permelec Ltd	Method for producing anode for alkaline water electrolysis, and anode for alkaline water electrolysis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1598686A (en) *	1977-04-29	1981-09-23	Dia Prosim	Enzymes immobilised on a resin via chelation with a metal
IT1207172B (it) *	1979-02-15	1989-05-17	Anic Spa	Processo per la preparazione dicorpi microporosi inglobanti uno o piu' agenti attivi.
ZA811368B (en) *	1980-03-24	1982-04-28	Genentech Inc	Bacterial polypedtide expression employing tryptophan promoter-operator
ES506955A0 (es) *	1980-11-10	1983-02-01	Genentech Inc	Un procedimiento para producir un polipeptido antiviral.
GB2108510B (en) *	1981-10-03	1984-12-12	Ciba Geigy Ag	Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof

1983
- 1983-10-25 CA CA000439666A patent/CA1252046A/en not_active Expired
- 1983-10-25 IE IE2493/83A patent/IE56509B1/en not_active IP Right Cessation
- 1983-10-27 IL IL70067A patent/IL70067A/xx not_active IP Right Cessation
- 1983-10-27 DE DE8383306548T patent/DE3376507D1/de not_active Expired
- 1983-10-27 AU AU20650/83A patent/AU559912B2/en not_active Expired
- 1983-10-27 EP EP83306548A patent/EP0108564B1/en not_active Expired
- 1983-10-28 NZ NZ206096A patent/NZ206096A/en unknown
- 1983-10-28 FI FI833952A patent/FI79411B/fi not_active Application Discontinuation
- 1983-10-31 DK DK498083A patent/DK498083A/da not_active Application Discontinuation
- 1983-11-01 GR GR72841A patent/GR78948B/el unknown
- 1983-11-03 ES ES526991A patent/ES8704005A1/es not_active Expired
- 1983-11-03 NO NO834014A patent/NO163986C/no not_active IP Right Cessation
- 1983-11-03 PH PH29782A patent/PH20994A/en unknown
- 1983-11-04 PT PT77605A patent/PT77605B/pt not_active IP Right Cessation
- 1983-11-04 BR BR8306175A patent/BR8306175A/pt unknown
- 1983-11-04 JP JP58207345A patent/JPH0728759B2/ja not_active Expired - Lifetime
1984
- 1984-06-04 ES ES533105A patent/ES533105A0/es active Granted
1992
- 1992-04-24 JP JP4131686A patent/JPH0759188B2/ja not_active Expired - Lifetime
1994
- 1994-11-29 JP JP6319042A patent/JP2716670B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DK498083D0 (da)	1983-10-31
EP0108564A1 (en)	1984-05-16
PH20994A (en)	1987-06-18
NO163986B (no)	1990-05-07
EP0108564B1 (en)	1988-05-04
JPH0759188B2 (ja)	1995-06-28
BR8306175A (pt)	1984-06-12
JPS59113898A (ja)	1984-06-30
NO834014L (no)	1984-05-07
DE3376507D1 (en)	1988-06-09
ES526991A0 (es)	1987-03-01
IL70067A0 (en)	1984-01-31
PT77605B (en)	1986-05-05
PT77605A (en)	1983-12-01
ES8704005A1 (es)	1987-03-01
CA1252046A (en)	1989-04-04
AU2065083A (en)	1984-05-10
GR78948B (no)	1984-10-02
JP2716670B2 (ja)	1998-02-18
IE832493L (en)	1984-05-04
ES8600215A1 (es)	1985-10-01
ES533105A0 (es)	1985-10-01
NO163986C (no)	1990-08-15
IL70067A (en)	1989-08-15
IE56509B1 (en)	1991-08-28
FI833952A (fi)	1984-05-05
JPH0728759B2 (ja)	1995-04-05
AU559912B2 (en)	1987-03-26
JPH05328965A (ja)	1993-12-14
DK498083A (da)	1984-05-05
NZ206096A (en)	1986-09-10
FI833952A0 (fi)	1983-10-28
JPH07215995A (ja)	1995-08-15

Legal Events

Date	Code	Title	Description
2004-08-31	FD	Application lapsed	Owner name: THE REGENTS OF THE UNIVERSITY OF

Publication	Publication Date	Title
FI79411B (fi)	1989-08-31	Foerfarande foer vaerdering av cellernas malignitet, vid foerfarandet anvaendbara antikroppar, antigener, deras framstaellning och anvaendning.
US4699877A (en)	1987-10-13	Methods and compositions for detecting human tumors
USRE35491E (en)	1997-04-08	Methods and compositions for detecting human tumors
JP3989528B2 (ja)	2007-10-10	Ｄｎａ配列及びエンコードされた***に特異的な乳癌たんぱく質
US6222020B1 (en)	2001-04-24	Antigens derived from the core protein of the human mammary epithelial mucin
EP1626084B1 (en)	2009-02-11	Compositions and methods for the diagnosis of tumours
EP1103623A1 (en)	2001-05-30	Human mucin core protein: nucleic acid probes, peptide fragments and antibodies thereto, and uses thereof in diagnostic and therapeutic methods
AU2003201315C1 (en)	2007-03-08	WNT-1 Induced secreted polypeptides; WISP-1, -2 and -3
US20060275783A1 (en)	2006-12-07	Gene markers for lung cancer
Nanus et al.	1990	Infrequent ras oncogene point mutations in renal cell carcinoma
Monnat et al.	1987	Prognostic implications of expression of the cellular genes myc, fos, Ha‐ras and Ki‐ras in colon carcinoma
US5182205A (en)	1993-01-26	Nucleotide sequences which are selectively expressed in pre-B cells and probes therefor
EP0269127B1 (en)	1994-02-23	Nucleotide sequences which are selectively expressed in pre-B cells and probes therefor
KR100948808B1 (ko)	2010-03-24	간암 마커로서의 ｌｃｎ2 유전자, 단백질 및 간암 진단키트
JP2008507261A (ja)	2008-03-13	肺癌診断のための新規のヌクレオチド配列およびアミノ酸配列、ならびにそのアッセイおよび使用方法
JP4782378B2 (ja)	2011-09-28	リンパ球異常増殖疾患の診断方法
JP4227881B2 (ja)	2009-02-18	成人ｔ細胞白血病診断薬
DK174459B1 (da)	2003-03-24	Fremgangsmåde til fremstilling af et antigenisk oligopeptid
DK174458B1 (da)	2003-03-24	Fremgangsmåde til fremstilling af et antigenisk oligopeptid
US5171850A (en)	1992-12-15	Intestinal oncofetal gene
KR100861465B1 (ko)	2008-10-02	위암 유발 유전자 ＺＮＦ312ｂ와 이에 의해 코드되는단백질 및 이를 이용한 위암 진단 키트
KR102110338B1 (ko)	2020-05-13	대장암 진단 마커로서의 신규 folr2 융합유전자 및 이의 용도
US20020071830A1 (en)	2002-06-13	Probe